



ARCALIS Minamisoma Facility Receives Good Design Award 2026

Minamisoma, Fukushima, Japan, October 15, 2026 – ARCALIS Inc. announced today that the entrance hall of its Minamisoma Facility (Headquarters), jointly submitted with Obayashi Corporation, has received the Good Design Award 2026, organized by the Japan Institute of Design Promotion.




**GOOD
DESIGN
AWARD
2026**



ARCALIS is engaged in the contract development and manufacturing organization (CDMO) business for messenger RNA (mRNA) pharmaceuticals. The Minamisoma Facility provides integrated services spanning research and development through commercial manufacturing of mRNA medicines and contributes to the advancement of the biopharmaceutical industry originating from Fukushima.


The award-winning entrance hall was designed to embody ARCALIS's aspiration to deliver a safer and healthier future to people around the world. The space expresses this vision through a dynamic architectural concept inspired by an endless star-filled sky.





The design incorporates a star chart of the spring night sky, reflecting the origin of the company name “ARCALIS” and its commitment to pursuing a bright future. A combination of highly reflective mirror glass and a carefully designed lighting system creates the impression of an infinitely expanding night sky. Ultra-small pinhole downlights of varying sizes are positioned according to the star chart, recreating the appearance of stars and completing the immersive space.

The name ARCALIS originates from a nova discovered in the vicinity of Arcturus, the brightest star in the constellation Boötes, and represents the company's mission to deliver a safer and more secure future worldwide. The entrance hall was conceived as a space where visitors can experience the company's philosophy and the value of its facility through an engaging and memorable environment.



By taking advantage of the high-ceiling structure characteristic of pharmaceutical manufacturing facilities, the design transforms vertical volume into a sense of limitless spatial expansion using reflective mirror glass. The result is a distinctive environment that provides visitors with a memorable introduction to ARCALIS and its vision for the future.

<About ARCALIS>

ARCALIS is Japan’s first mRNA CDMO headquartered in Minamisoma. In July 2023, we completed our drug substance manufacturing facility at the Minamisoma site and have since successfully commenced commercial production and shipment of mRNA vaccine drug substances. In February 2026, we further expanded our manufacturing capabilities with the completion of a drug product facility adjacent to the drug substance building, enabling rapid domestic production of infectious disease vaccines during public health emergencies. We provide seamless, end-to-end services for mRNA vaccines and therapeutics — from process development to commercial manufacturing — for pharmaceutical companies and biotech ventures in Japan and around the world.

For more information, please visit <https://corp.arcalis.co.jp/en/>